Balance Sheet Insights: Immunovant Inc (IMVT)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

In the latest session, Immunovant Inc (NASDAQ: IMVT) closed at $29.76 up 0.61% from its previous closing price of $29.58. In other words, the price has increased by $0.61 from its previous closing price. On the day, 0.8 million shares were traded. IMVT stock price reached its highest trading level at $29.96 during the session, while it also had its lowest trading level at $28.9.

Ratios:

For a deeper understanding of Immunovant Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.14 and its Current Ratio is at 22.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $50.

On March 13, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $50.

On February 20, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $51.JP Morgan initiated its Overweight rating on February 20, 2024, with a $51 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 24 ’24 when Stout Jay S sold 7,239 shares for $28.90 per share. The transaction valued at 209,207 led to the insider holds 147,739 shares of the business.

Levine Mark S. sold 3,963 shares of IMVT for $114,531 on Apr 24 ’24. The Chief Legal Officer now owns 343,156 shares after completing the transaction at $28.90 per share. On Apr 24 ’24, another insider, Geffner Michael, who serves as the Chief Medical Officer of the company, sold 3,261 shares for $28.90 each. As a result, the insider received 94,243 and left with 141,616 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4323919360 and an Enterprise Value of 3607134976.

Stock Price History:

Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is -4.03%, while the 200-Day Moving Average is calculated to be -8.03%.

Shares Statistics:

For the past three months, IMVT has traded an average of 1.14M shares per day and 1027180 over the past ten days. A total of 130.33M shares are outstanding, with a floating share count of 60.55M. Insiders hold about 58.33% of the company’s shares, while institutions hold 46.10% stake in the company. Shares short for IMVT as of 1713139200 were 8508700 with a Short Ratio of 7.46, compared to 1710460800 on 9354237. Therefore, it implies a Short% of Shares Outstanding of 8508700 and a Short% of Float of 12.1700004.

Most Popular

[the_ad id="945"]